Prospective, Randomized, Double-Blind Trial of Adjuvant Exisulind Versus Placebo for Patients at Risk for Prostate Cancer Recurrence After Radical Prostatectomy
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention
Assess efficacy of drug vs placebo regarding overall rate of biochemical progression
Bradley C. Leibovich, M.D.
United States: Food and Drug Administration
|Mayo Clinic||Rochester, Minnesota 55905|